Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more
Market Cap & Net Worth: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (SHE:300357) has a market capitalization of $1.79 Billion (CN¥13.12 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #7775 globally and #1384 in its home market, demonstrating a 2.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's stock price CN¥25.06 by its total outstanding shares 523584000 (523.58 Million).
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.05 Billion to $1.79 Billion (7.98% CAGR).
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.57x
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market cap is 1.57 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
4.56x
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market cap is 4.56 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.05 Billion | $267.11 Million | $117.82 Million | 3.95x | 8.95x |
| 2016 | $735.66 Million | $312.09 Million | $129.20 Million | 2.36x | 5.69x |
| 2017 | $1.04 Billion | $385.58 Million | $186.10 Million | 2.70x | 5.59x |
| 2018 | $1.42 Billion | $500.74 Million | $232.88 Million | 2.83x | 6.08x |
| 2019 | $3.07 Billion | $639.35 Million | $298.30 Million | 4.80x | 10.30x |
| 2020 | $5.35 Billion | $636.21 Million | $278.45 Million | 8.41x | 19.23x |
| 2021 | $4.01 Billion | $807.69 Million | $337.99 Million | 4.96x | 11.86x |
| 2022 | $3.87 Billion | $896.02 Million | $348.77 Million | 4.32x | 11.10x |
| 2023 | $2.05 Billion | $848.19 Million | $310.18 Million | 2.42x | 6.61x |
| 2024 | $1.45 Billion | $925.39 Million | $317.82 Million | 1.57x | 4.56x |
Competitor Companies of 300357 by Market Capitalization
Companies near Zhejiang Wolwo Bio-Pharmaceutical Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Zhejiang Wolwo Bio-Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's market cap moved from $1.05 Billion to $ 1.79 Billion, with a yearly change of 7.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.79 Billion | -11.60% |
| 2025 | CN¥2.02 Billion | +39.52% |
| 2024 | CN¥1.45 Billion | -29.27% |
| 2023 | CN¥2.05 Billion | -47.06% |
| 2022 | CN¥3.87 Billion | -3.40% |
| 2021 | CN¥4.01 Billion | -25.12% |
| 2020 | CN¥5.35 Billion | +74.28% |
| 2019 | CN¥3.07 Billion | +116.82% |
| 2018 | CN¥1.42 Billion | +36.18% |
| 2017 | CN¥1.04 Billion | +41.41% |
| 2016 | CN¥735.66 Million | -30.20% |
| 2015 | CN¥1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.79 Billion USD |
| MoneyControl | $1.79 Billion USD |
| MarketWatch | $1.79 Billion USD |
| marketcap.company | $1.79 Billion USD |
| Reuters | $1.79 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.